BETA
BETA
GoodRx Holdings
GDRX64
$8.85arrow_drop_up1.25%$0.11
GDRX64
$8.85
arrow_drop_up1.25%Performance History
| Key Stats | |
|---|---|
| Open | $8.95 |
| Prev. Close | $8.97 |
| EPS | -0.01 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 8.65 | 9.26 |
| 52 Week Range | 4.13 | 9.37 |
| Ratios | |
|---|---|
| EPS | -0.01 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About GoodRx Holdings (GDRX)
- Sector
- Healthcare
- Industry
- Health Information Services
- CEO
- Headquarters
- Santa Monica
- Employees
- 952
- Exchange
- NASDAQ
Keep an eye on GoodRx Holdings
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is GoodRx Holdings 's (GDRX) price per share?
The current price per share for GoodRx Holdings (GDRX) is $8.85. The stock has seen a price change of $0.11 recently, indicating a 1.26% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for GoodRx Holdings (GDRX)?
For GoodRx Holdings (GDRX), the 52-week high is $9.37, which is 5.88% from the current price. The 52-week low is $4.14, the current price is 114.03% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is GoodRx Holdings (GDRX) a growth stock?
GoodRx Holdings (GDRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying GoodRx Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is GoodRx Holdings (GDRX) stock price performance year to date (YTD)?
As of the latest data, GoodRx Holdings (GDRX) has a year-to-date price change of 57.47%. Over the past month, the stock has experienced a price change of 13.17%. Over the last three months, the change has been 25%. Over the past six months, the figure is 35.94%.
help
Is GoodRx Holdings (GDRX) a profitable company?
GoodRx Holdings (GDRX) has a net income of -$8.87M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 77.33% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 10.3% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $750.26M, although specific revenue growth data is currently not available. The gross profit is $580.17M. Operating income is noted at $51.38M. Furthermore, the EBITDA is $108.03M.
help
What is the market capitalization of GoodRx Holdings (GDRX)?
GoodRx Holdings (GDRX) has a market capitalization of $3.41B. The average daily trading volume is 1.15M, indicating the stock's liquidity and investor engagement.
News
GOODRX
RBC CAPITAL
OUTPERFORM
MONTHLY ACTIVE CONSUMERS
REVENUE GROWTH
EBITDA MARGIN
7/17/2024RBC holds firm on GoodRx stock target with Outperform rating - Investing.com
ANALYST RATINGS
6/10/2024The Analyst Landscape: 7 Takes On GoodRx Holdings
NEWS
UPGRADES
HEALTH CARE
PRICE TARGET
ANALYST RATINGS
GENERAL
5/23/2024GoodRx Strengthens Core Business With New Initiatives, Analyst Upgrades On Potential Opportunities
ANALYST RATINGS
5/16/2024Forecasting The Future: 13 Analyst Projections For GoodRx Holdings
5/12/2024
Wall Street Breakfast: The Week Ahead
5/10/2024
GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.